1) Gorman JM : Comorbid depression and anxiety spectrum disorders. Depress Anxiety 4 : 160-168, 1996-1997
2) 石郷岡純, 中村祐, 君田仲生ほか : うつ病と不安-不安について考える-. 臨床精神薬理 11 : 1391-1406, 2008
3) Lin CH, Wang FC, Lin SC et al : A comparison of inpatients with anxious depression to those with nonanxious depression. Psychiatry Res 220 : 855-860, 2014
4) Fava M, Rush AJ, Alpert JE et al : Difference in treatment outcome in outpatients with anxious versus nonanxious depression : a STAR*D report, Am. J Psychiatry 165 : 342-351, 2008
5) Dombrovski AY, Mulsant BH, Houck PR et al : Residual symptoms and recurrence during maintenance treatment of late-life depression. J Affact Disord 103 : 77-82, 2007
6) Sakurai H, Uchida H, Abe T et al : Trajectories of individual symptoms in remitters versus non-remitters with depression, J Affect Disord 151 : 506-513, 2013
7) Papakostas GI, Larsen K : Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. Eur Arch Psychiatry Clin Neurosci 261 : 147-156, 2011
8) Saveanu R, Etkin A, Duchemin AM et al : The international Study to Predict Optimized Treatment in Depression (iSPOT-D) : outcomes from the acute phase of antidepressant treatment. J Psychiatr Res 61 : 1-12, 2015
9) Lam RW, Parikh SV, Michalak EE et al : Canadian Network for Mood and Anxiety Treatments (CANMAT) consensus recommendations for functional outcomes in major depressive disorder. Ann Clin Psychiatry 27 : 142-149, 2015
10) Boulenger JP, Hermes A, Huusom AK et al : Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression : escitalopram vs paroxetine. Curr Med Res Opin 26 : 605-614, 2010
11) Olie JP, Tonnoir B, Menard F et al : A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety. Depress Anxiety 24 : 318-324, 2007
12) 大下隆司 : エスシタロプラムの抑うつおよび不安に対する効果. Depression Journal 1 : 92-95, 2013
13) Hashimoto S, Inoue T, Muraki I et al : Effects of acute citalopram on the expression of conditioned freezing in naive versus chronic citalopram-treated rats. Prog Neuropsychopharmacol Biol Psychiatry 33 : 113-117, 2009
14) 井上猛, 小山司 : 不安障害における扁桃体セロトニンの役割. 心身医学 49 : 291-297, 2009
15) Sanchez C, Reines EH, Montgomery SA : A comparative review of escitalopram, paroxetine, and sertraline : Are they all alike? Int Clin Psychopharmacol 29 : 185-196, 2014
16) Shinkai K, Yoshimura R, Ueda N et al : Associations between baseline plasma MHPG (3-methoxy-4-hydroxyphenylglycol) levels and clinical responses with respect to milnacipran versus paroxetine treatment. J Clin Psychopharmacol 24 : 11-17, 2004